Replimune Group Inc (REPL) Stock Price, Quote & News

Company Profile

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express a...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 222 9600

Website: www.replimune.com

Address:

500 Unicorn Park Drive, Suite 303, Woburn, United States

Merlintrader Jul. 25 at 5:36 PM

$SLS $TLX $REPL $EYPT The Top Ten Biotech Stocks Right Now https://www.merlintrader.com/top-ten-biotech-stocks-right-now/

0 · Reply

Stocks_Spot Jul. 25 at 3:58 PM

$REPL remains primarily an FDA event trade. The bull case: the FDA has accepted the resubmitted BLA for RP1 combined with nivolumab in advanced melanoma. This revives a regulatory path that appeared close to dead after the previous rejections. The risk has now shifted to the final FDA decision, cash requirements and potential dilution. Replimune is asking shareholders to increase authorized common shares from 150 million to 300 million. This does not create immediate dilution, but it would give the company significantly more flexibility to raise capital later. Bottom line: a powerful regulatory catalyst, but still a highly speculative biotech position with binary outcome risk. Not financial advice. Always do your own research.

1 · Reply

beachsidefreddy Jul. 25 at 2:55 PM

$REPL preverication is not a word BAKER BROS adhere to!!

0 · Reply

BonnieSapien Jul. 25 at 2:50 PM

$ZENA ZenaTech's Drone as a Service Closes 26th Acquisition of an Ohio-based Land Surveying Company Licensed in Four States https://finance.yahoo.com/technology/articles/zenatechs-drone-closes-26th-acquisition-113000524.html $REPL $UCO $F

1 · Reply

beachsidefreddy Jul. 25 at 2:26 PM

$REPL Worth noting: this doesn’t dilute share count (those shares already exist or are covered by warrants already outstanding) — it just gives Baker Brothers the ability to sell into the market whenever they choose. Given REPL’s annual meeting on September 15, 2026 also includes a proposal to double authorized shares from 150 million to 300 million , that’s a separate item worth watching alongside this filing, especially with earnings context and the going-concern overhang you’ve been tracking.

0 · Reply

Macdaddy23 Jul. 25 at 2:00 PM

$REPL Baker Bros going to dump 25M shares on the market before AdCom with that registration statement? Interesting to see what happens leading up to it and whether we will see sharp sell off like what happened going into April before the last CRL.

1 · Reply

Tom2772 Jul. 25 at 4:51 AM

$OTLK $REPL $SLS Short interest dropped nearly 20% from 14.0M to 11.2M shares. Some bears have already covered, but over 11M shares remain short. With FDA approval secured, the focus now shifts to commercialization. Nothing is over. Know what you own. 💎 https://www.nasdaq.com/market-activity/stocks/otlk/short-interest

2 · Reply

StocktwitsNews Jul. 25 at 12:30 AM

FDA Showdown Week: CAPR, NRXP, REPL And MRNA Face Make-Or-Break Regulatory Decisions $CAPR $VTRS $REPL $MRNA https://stocktwits.com/news/equity/markets/fda-showdown-week-capr-nrxp-repl-and-mrna-face-make-or-break-regulatory-decisions/cZZrkVjR7zK

1 · Reply

Tom2772 Jul. 24 at 8:32 PM

$OTLK $REPL $REGN 🇺🇸🇪🇺 U.S. & European Expansion | Commercial Launch 🚀 🇺🇸 United States: FDA approved. First and only FDA-approved ophthalmic bevacizumab for wet AMD. 12 years of regulatory exclusivity. Commercial launch with Cencora underway. 🚀 🇪🇺 European Union: Approved by the European Commission – commercial rollout underway. 🇬🇧 United Kingdom: MHRA approved – commercially available. 🇩🇪 Germany: Commercially available. 🇦🇹 Austria: Commercially available. 🇳🇱 Netherlands & 🇮🇪 Ireland: Next planned launches. 🇫🇷 France, 🇮🇹 Italy & 🇪🇸 Spain: Planned expansion. 🇨🇭 Switzerland: Exclusive partnership with Mediconsult AG. In preparation for commercialization, Outlook has built a strong commercial organization by adding key leadership across HCP Marketing, Market Access, Pricing & Contracting, Trade & Distribution, Patient Access, Customer Engagement & Strategic Innovation, Executive Leadership The foundation is in place. Now it's all about execution. 🚀💎

0 · Reply

beachsidefreddy Jul. 24 at 8:19 PM

$REPL stock needs to go to $15 for that buyer to break even NOT HAPPENING WITH OR WITHOUT FDA…IOVA OWNS MELANOMA

1 · Reply

Replimune Group Registration statement: Registration filing

2026-07-20T15:15:07.000Z - 5 days ago

Replimune Group put volume heavy and directionally bearish

Jul 15, 2026, 11:28 AM EDT - 10 days ago

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Replimune Group, Inc. (REPL)

Jul 13, 2026, 8:00 AM EDT - 12 days ago

Replimune Group Proxy statement: Proxy filing

2026-07-08T16:35:10.000Z - 17 days ago

Replimune Group put volume heavy and directionally bearish

2026-07-07T19:20:10.000Z - 17 days ago

Replimune Group put volume heavy and directionally bearish

2026-06-30T11:50:26.000Z - 25 days ago

Replimune price target raised to $9 from $6 at Wedbush

2026-06-30T11:00:23.000Z - 25 days ago

BMO double upgrades Replimune on higher chances of FDA approval

2026-06-29T15:15:09.000Z - 26 days ago

Replimune Group put volume heavy and directionally bearish

Jun 29, 2026, 8:00 AM EDT - 26 days ago

Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update

Jun 29, 2026, 8:00 AM EDT - 26 days ago

Replimune Group Earnings release: Q4 2026

Jun 29, 2026, 8:00 AM EDT - 26 days ago

Replimune Group Annual report: Q4 2026

2026-06-26T15:40:10.000Z - 4 weeks ago

JPMorgan upgrades Replimune on RP1 application resubmission

2026-06-26T15:35:11.000Z - 4 weeks ago

Replimune upgraded to Overweight from Neutral at JPMorgan

2026-06-26T12:15:33.000Z - 4 weeks ago

Replimune announces FDA acceptance of RP1 biologics license application

Jun 26, 2026, 8:00 AM EDT - 4 weeks ago

Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma

2026-06-01T16:21:43.000Z - 7 weeks ago

Replimune Group trading resumes

2026-06-01T13:36:30.000Z - 7 weeks ago

Replimune Group trading halted, volatility trading pause

2026-06-01T13:07:02.000Z - 7 weeks ago

Replimune price target raised to $6 from $2 at Wedbush

2026-05-31T21:15:05.000Z - 7 weeks ago

Replimune presents final first-in-human data for RP2 alone, with nivolumab

2026-05-31T20:35:04.000Z - 7 weeks ago

Replimune presents 3-year overall survival data from IGNYTE trial

May 31, 2026, 8:00 AM EDT - 7 weeks ago

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

May 30, 2026, 8:00 AM EDT - 2 months ago

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

May 29, 2026, 9:53 PM EDT - 2 months ago

How Replimune's drug got a third chance after the White House intervened

May 29, 2026, 8:51 AM EDT - 2 months ago

Replimune to resubmit twice-rejected drug for approval after FDA shakeup

May 29, 2026, 8:07 AM EDT - 2 months ago

Replimune reaches agreement with US FDA to resubmit melanoma drug application

May 29, 2026, 8:00 AM EDT - 2 months ago

Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA

May 29, 2026, 7:30 AM EDT - 2 months ago

Replimune Gets Third Try at FDA Approval After Makary Departure

May 5, 2026, 10:58 AM EDT - 2 months ago

FDA Commissioner Makary defends agency's decision on Replimune's drug

Apr 22, 2026, 12:56 PM EDT - 3 months ago

US Health Secretary Kennedy distances himself from FDA's Replimune cancer drug rejection

Apr 13, 2026, 11:46 AM EDT - 3 months ago

Replimune co-founder calls FDA rejection of melanoma drug ‘unfair'

Apr 10, 2026, 5:02 PM EDT - 3 months ago

Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma

Apr 10, 2026, 11:24 AM EDT - 3 months ago

US FDA declines to approve Replimune's drug for advanced skin cancer

Mar 9, 2026, 2:20 PM EDT - 4 months ago

Replimune Group Transcript: Leerink Global Healthcare Conference 2026

Mar 2, 2026, 8:00 AM EST - 5 months ago

Replimune to Present at Two Upcoming Investor Conferences

Feb 3, 2026, 8:00 AM EST - 6 months ago

Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

Feb 3, 2026, 8:00 AM EST - 6 months ago

Replimune Group Quarterly report: Q3 2026

Feb 3, 2026, 8:00 AM EST - 6 months ago

Replimune Group Earnings release: Q3 2026

Jan 14, 2026, 4:30 PM EST - 6 months ago

Replimune Group Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 4:30 PM EST - 6 months ago

Replimune Group Slides: 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 8:00 AM EST - 7 months ago

Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference

Nov 7, 2025, 4:45 PM EST - 9 months ago

Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)

Nov 6, 2025, 8:30 AM EST - 9 months ago

Replimune Group Earnings release: Q2 2026

Nov 6, 2025, 8:30 AM EST - 9 months ago

Replimune Group Quarterly report: Q2 2026

Nov 6, 2025, 8:00 AM EST - 9 months ago

Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update

Nov 6, 2025, 7:00 AM EST - 9 months ago

Replimune Group Registration statement: Registration Filing

Oct 20, 2025, 7:00 AM EDT - 9 months ago

Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma

Oct 19, 2025, 8:00 AM EDT - 9 months ago

Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025

Sep 18, 2025, 9:15 AM EDT - 11 months ago

Replimune Provides Update Following Type A Meeting with FDA

Sep 3, 2025, 11:30 AM EDT - 11 months ago

Replimune Group Transcript: AGM 2025

Sep 2, 2025, 8:00 AM EDT - 11 months ago

Replimune Announces Type A Meeting Scheduled with FDA

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update

Merlintrader Jul. 25 at 5:36 PM

$SLS $TLX $REPL $EYPT The Top Ten Biotech Stocks Right Now https://www.merlintrader.com/top-ten-biotech-stocks-right-now/

0 · Reply

Stocks_Spot Jul. 25 at 3:58 PM

1 · Reply

beachsidefreddy Jul. 25 at 2:55 PM

$REPL preverication is not a word BAKER BROS adhere to!!

0 · Reply

BonnieSapien Jul. 25 at 2:50 PM

1 · Reply

beachsidefreddy Jul. 25 at 2:26 PM

0 · Reply

Macdaddy23 Jul. 25 at 2:00 PM

1 · Reply

Tom2772 Jul. 25 at 4:51 AM

2 · Reply

StocktwitsNews Jul. 25 at 12:30 AM

1 · Reply

Tom2772 Jul. 24 at 8:32 PM

0 · Reply

beachsidefreddy Jul. 24 at 8:19 PM

$REPL stock needs to go to $15 for that buyer to break even NOT HAPPENING WITH OR WITHOUT FDA…IOVA OWNS MELANOMA

1 · Reply

OptionRunners Jul. 24 at 5:34 PM

$REPL August call buyer coming in

2 · Reply

President_Dwayne_Camacho Jul. 24 at 4:41 PM

$REPL This is really a coin flip.

0 · Reply

beachsidefreddy Jul. 24 at 3:58 PM

$REPL where does REPL live? Answer CRL CITY!!

1 · Reply

Dmoney136 Jul. 24 at 12:40 AM

$REPL is that a head and shoulders I see?

0 · Reply

ChartExplorers Jul. 23 at 11:35 PM

$AGL $REPL \\

0 · Reply

Charlie_Omaha Jul. 23 at 5:28 PM

$IOVA funds defended $5 which is a liquidation number for some . So let's see how this will hold into next week $REPL approval. Not very optimistic short term. This can fall to 4.5 just like that on no news due to gravity. Overall happy move but short term gyrations and lack of exciting management is killing the stock.

0 · Reply

MoneyMaker91905 Jul. 23 at 4:39 PM

$REPL https://seekingalpha.com/article/4924759-replimunes-rp1-drug-probably-works-but-its-not-a-buy-yet

1 · Reply

Tom2772 Jul. 23 at 1:44 PM

$OTLK $REPL $REGN The situation looks never better so when $ 3 ?

0 · Reply

Charlie_Omaha Jul. 23 at 12:10 PM

$IOVA Likely to drift towards 4.6 before adcom and August 2nd $REPL announcement. Then drop to 3.7 on approval and another long road to recover after ER and towards October lung and front line announcement. ER will be a dud, as always under Fred. I love the TIL but not the management.

2 · Reply

Tom2772 Jul. 23 at 6:57 AM

$OTLK $REPL $REGN Yes, so much more..💎💎💪 European Expansion & Commercial Launch 🇪🇺 European Union: Approved by the European Commission – commercial rollout underway. 🇬🇧 United Kingdom: MHRA approved – commercially available. 🇩🇪 Germany: Commercially available. 🇦🇹 Austria: Commercially available. 🇳🇱 Netherlands & 🇮🇪 Ireland: Planned next launches. 🇫🇷 France, 🇮🇹 Italy & 🇪🇸 Spain: Planned expansion. 🇨🇭 Switzerland: Exclusive partnership with Mediconsult AG. 🇺🇸 United States: Following FDA approval, commercial launch with Cencora. In preparation for commercialization, Outlook is actively building its commercial organization by adding key leadership roles across HCP Marketing, Market Access, Pricing & Contracting, Trade & Distribution, Patient Access, Customer Engagement & Strategic Innovation, Executive Leadership, and a new Executive Assistant to the C-Suite.

0 · Reply

flytrader1 Jul. 22 at 4:48 PM

$REPL FYI - People are betting this goes below $1.00 in the next 30 days🤔

1 · Reply

QuantInsider Jul. 22 at 2:54 AM

$REPL just ripped about 16% in five days, up 4.7% today But what's really going on Not much in the options flow, just a big August put sweep that's way out of the money Looks more like someone hedging against a dip than betting on a crash With that implied vol at around 454%, it seems like tail-risk insurance If you're thinking about jumping in, maybe stick to defined-risk plays No high conviction edge here from the flow Stay cautious chasing that upside

1 · Reply

Market Cap	878.07M
Revenue (ttm)	0.00
Net Income (ttm)	-313.94M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.50

Volume	3,267,400
Avg Vol	5,116,200
Day's Range	N/A - N/A
Shares Out	83.95M
Stochastic %K	34%
Beta	0.86
Analysts	Sell
Price Target	$10.67